quinaprilat has been researched along with avapro in 2 studies
| Studies (quinaprilat) | Trials (quinaprilat) | Recent Studies (post-2010) (quinaprilat) | Studies (avapro) | Trials (avapro) | Recent Studies (post-2010) (avapro) |
|---|---|---|---|---|---|
| 92 | 23 | 4 | 1,369 | 385 | 495 |
| Protein | Taxonomy | quinaprilat (IC50) | avapro (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 7.3067 | |
| Type-1 angiotensin II receptor | Homo sapiens (human) | 0.0099 | |
| Type-2 angiotensin II receptor | Homo sapiens (human) | 0.003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Danser, AH; de Vries, R; Saxena, PR; Schalekamp, MA; Schuijt, MP | 1 |
2 other study(ies) available for quinaprilat and avapro
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Vasoconstriction is determined by interstitial rather than circulating angiotensin II.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Carotid Arteries; Dose-Response Relationship, Drug; Femoral Artery; Imidazoles; In Vitro Techniques; Irbesartan; Isoquinolines; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Swine; Tetrahydroisoquinolines; Tetrazoles; Vasoconstriction; Vasoconstrictor Agents | 2002 |